BIO-TECHNE Corp vs Xcel Energy Inc — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while Xcel Energy Inc trades at $73.36 (market cap $45.82B). The key difference: Xcel Energy Inc is far larger — about 4× BIO-TECHNE Corp's market cap, and Xcel Energy Inc pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Xcel Energy Inc for 61 Days on average.
| TECH | XEL | |
|---|---|---|
Market Cap | $11.36B | $45.82B |
Volume | 5,390,331 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $72.61 | $83.91 |
52-Week Low | $43.31 | $69.39 |
Typical Hold Time | 63 Days | 61 Days |
Enterprise Value | $11.39B | $84.14B |
Dividend Yield | 0.44% | 3.23% |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Xcel Energy (XEL) trades at $72.42, down 0.43% with a bearish technical signal despite recent earnings beats. The stock shows solid fundamentals with $14.67B revenue, 15.28% net margin, and consistent cash flow growth. Analyst consensus is bullish with a $90.83 price target (62.96% buy rating), while institutional activity shows mixed positioning. Recent news highlights data center power demand growth and wildfire liability concerns.
XEL offers attractive utility exposure with 11% rate base growth potential and dividend stability, but faces regulatory and wildfire litigation risks. The current valuation at 20.1x P/E appears reasonable given earnings trajectory, though technical weakness near support at $71-72 requires monitoring for entry points.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →